Cellosaurus logo
expasy logo

Cellosaurus LoVo-92 (CVCL_5237)

[Text version]
Cell line name LoVo-92
Synonyms Lovo-92; Lovo 92; Lovo92
Accession CVCL_5237
Resource Identification Initiative To cite this cell line use: LoVo-92 (RRID:CVCL_5237)
Comments Population: Caucasian.
Derived from site: Metastatic; Left supraclavicular lymph node; UBERON=UBERON_8480056.
Sequence variations
  • Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line).
  • Mutation; HGNC; 583; APC; Simple; p.Arg1114Ter (c.3340C>T); ClinVar=VCV000236589; Zygosity=Heterozygous (from parent cell line).
  • Mutation; HGNC; 583; APC; Simple; p.Met1431fs*42 (c.4289delC) (p.T1430fs); Zygosity=Heterozygous (from parent cell line).
  • Mutation; HGNC; 583; APC; Simple; p.Arg2816Gln (c.8447G>A); ClinVar=VCV000419681; Zygosity=Heterozygous (from parent cell line).
  • Mutation; HGNC; 914; B2M; Simple; p.Leu15Phefs*41 (c.43_44delCT); Zygosity=Heterozygous (from parent cell line).
  • Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line).
  • Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line).
  • Mutation; HGNC; 6768; SMAD2; Simple; p.Ala292Val (c.875C>T); Zygosity=Heterozygous (from parent cell line).
Disease Colon adenocarcinoma (NCIt: C4349)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0399 (LoVo)
Children:
CVCL_6A75 (Lovo-143X19)CVCL_6A76 (Lovo-143X3)CVCL_5235 (Lovo-175X2)
CVCL_5236 (Lovo-273X17)CVCL_5238 (LoVo-li)CVCL_E0XG (Ubigene LoVo ATF1 KO)
CVCL_E0XH (Ubigene LoVo OLA1 KO)
Sex of cell Male
Age at sampling 56Y
Category Cancer cell line
Publications

PubMed=8632910
Pocard M., Chevillard S., Villaudy J., Poupon M.-F., Dutrillaux B., Remvikos Y.
Different p53 mutations produce distinct effects on the ability of colon carcinoma cells to become blocked at the G1/S boundary after irradiation.
Oncogene 12:875-882(1996)

PubMed=9989828; DOI=10.1038/sj.onc.1202336
Soulie P., Poupon M.-F., Remvikos Y., Dutrillaux B., Muleris M.
Distinct chromosomal alterations associated with TP53 status of LoVo cells under PALA selective pressure: a parallel with cytogenetic pathways of colorectal cancers.
Oncogene 18:775-781(1999)

PubMed=17339891; DOI=10.1038/sj.bjc.6603639; PMCID=PMC2360080
Giovannetti E., Backus H.H.J., Wouters D., Ferreira C.G., van Houten V.M.M., Brakenhoff R.H., Poupon M.-F., Azzarello A., Pinedo H.M., Peters G.J.
Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels.
Br. J. Cancer 96:769-775(2007)

PubMed=18600534; DOI=10.1080/15257770802145512
Giovannetti E., Backus H.H.J., Wouters D., Peters G.J.
Functional inactivity and mutations of p53 differentially affect sensitivity to 5-fluorouracil and antifolate inhibitors of thymidylate synthase (TS) by altering TS levels in colorectal cancer cells.
Nucleosides Nucleotides Nucleic Acids 27:740-745(2008)

Cross-references
Cell line databases/resources cancercelllines; CVCL_5237
Anatomy/cell type resources BTO; BTO:0004146
Encyclopedic resources Wikidata; Q54902900
Gene expression databases GEO; GSM503149
Polymorphism and mutation databases Progenetix; CVCL_5237
Entry history
Entry creation04-Apr-2012
Last entry update05-Oct-2023
Version number20